Transforming R&D with Generative AI and Real-World Data

Ryan Fukushima, Chief Operating Officer at Tempus, and Robert Shoemaker, Ph.D., Senior Vice President of Research at Erasca, Inc., spoke about the transformative power of artificial intelligence in oncology research and drug development at the AACR Annual Meeting 2025.

Jul 01, 2025
Life Sciences
Video
Smiling man with glasses in a black and white professional headshot.Ryan FukushimaChief Operating Officer, Tempus
Black and white headshot of a smiling man with short graying hair in a dark shirt.Robert Shoemaker, Ph.D.Senior Vice President, Research at Erasca, Inc.

Related content

Simple white graphic of a single sheet of paper or document, slightly angled.Article
Person works on computer with abstract digital code and data patterns overlayed.

Bridging the gap: How Target Trial Emulation transforms real-world data into credible evidence

2026-08-20
Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Abstract digital background with glowing white lines and a fading dotted pattern.

Q&A: Predicting response and resistance in ADCs with AI and multimodal data

2026-08-20
Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Abstract background with light grey gradient, digital dots, and subtle wave patterns.

Researchers across pharma and academia are reducing oncology drug timelines with Tempus Lens

2026-08-12
Life Sciences